E-poster
HCV
Lai Wei P-055 Daclatasvir plus asunaprevir for the treatment of HCV genotype 1b infection in Chinese patients with or without compensated cirrhosis: an integrated analysis
Ming-Lung Yu P-056 Real-World Sustained Virologic Response Rates (SVR12) withInterferon (IFN)-Free Direct Acting Antiviral (DAA) Therapy inEast Asia- Results from REAL-C (Real-World Effectiveness from the Asia Liver Consortium for Chronic Hepatitis C)
Chun-ming Hong P-058 Real-World Experience of Direct-Acting Antiviral Agents for Chronic Hepatitis C Patients in Taiwan
Pin-nan Cheng P-059 Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
Batbold Batsaikhan P-060 The Effect of Antiviral Therapy on Serum Lipid Profiles in Chronic Hepatitis C
Jyh-jou Chen P-061 Genotype 6 HCV infection in a high endemic area of chronic hepatitis C in southern Taiwan.
Batbold Batsaikhan P-062 Elevated Serum Ferritin Level Associated with Hepatic Steatosis and Fibrosis in Hepatitis C Virus Infected Patients
Chih Han Liu P-063 Real-world safety and efficacy of Paritaprevir/ritonavir/ombitasvir plus dasabuvir +/- ribavirin in patients with hepatitis C virus genotype 1 and compensated advanced fibrosis: a multicenter pooled analysis
Tyng Yuan Jang P-064 Augmentation of serum uric acid in chronic hepatitis C patients with curative antivirals
Yasir Waheed P-065 Hepatitis C in Pakistan and analysis of HCV Polymerase gene from Pakistani Isolates
ChienHung Lin P-066 The real world data of one year post Taiwan's national health insurance DAA reimbursement for chronic hepatitis C : an experience from primary care clinic
Pin-Nan Cheng P-067 The real world experience of grazoprevir/elbasivr treatment for chronic hepatitis C in a single hospital of southern Taiwan
Tung-hung Su P-068 Early antiviral therapy reduces the risk of lymphoma in chronic hepatitis C patients
Xiaoying Zhang P-069 Emergence of resistant variants detected after Daclatasvir/Asunaprevir combination therapy in a compensated cirrhosis patient infected with HBV/HCV co-infection: a case report
Wei-yu Kao P-070 Regression of liver stiffness assessed through transient elastography in patients with chronic hepatitis C receiving direct acting antiviral agents
Ming-Chao Tsai P-071 Renal safety of directly acting antivirals treatment in chronic hepatitis C patients: real world experience
Chengzhen Lu P-072 Real-world Effectiveness and Safety Experience of Daclatasvir and Asunaprevir treatment in Chinese patients with hepatitis C genotype 1b infection
Yen-Chih Lin P-073 PrOD :Taiwan- real world data from Changhua Christian Hospital
Tyng Yuan Jang P-074 Association of hyperuricemia with disease severity in chronic hepatitis C patients
Ming-Ying Lu P-075 Elevated Interleukin-4 Levels Predicted Advanced Fibrosis in Chronic Hepatitis C
Tsung-ming Chen P-076 Elimination of hepatitis C virus by pegylated interferon and ribavirin after curative treatment for early hepatocellular carcinoma provided a favorable overall survival: a time-dependent analysis
Hsueh-Chou Lai P-077 Efficacy and Safety of Direct-Acting Antivirals in Treatment-naïve and-experienced Patients with Chronic Hepatitis C: a real-world preliminary result
Ming Chao Tsai P-078 The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in southern Taiwan
Sih Hsien Wu P-079 Real-world Experience of Efficacy and Safety Using Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir for Advanced Fibrotic Genotype 1 Chronic Hepatitis C Patients Who Failed to Previous Therapy with Pegylated Interferon Plus Ribavirin
Sou Fai-meng P-080 The comparison of clinical characteristics and prognosis of HCC after antiviral therapy for HCV patients between SVR and non-SVR patients
Chung-feng Huang P-081 Dynamic changes of serum MHC class I chain-related A protein predict hepatocellular carcinoma in chronic hepatitis C patients after viral eradication
Sheng-Hung Chen P-082 Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis C on and off Treatment
Chih-Lang Lin P-083 Dual oral therapy with daclatasvir plus asunaprevir for patients with HCV genotype 1b infection: A Chang Gung Medical Branches multicenter experience
Shi Chi Wen P-084 Treatment with Pegylated Interferon Alfa-2a plus Lower Dose Ribavirin for Hemodialysis Patients with Chronic Hepatitis C
Hung-Chih Chiu P-085 The knowledge and will of treatment for chronic hepatitis C patients in the era of direct antiviral agents
Chun-han Cheng P-086 Histological response in chronic hepatitis C patients with sustained virological response
Batbold Batsaikhan P-088 Association between Fibrosis Marker and Cryoglobulinemia in Patients with Chronic Hepatitis C
Chia-Yen Dai P-089 Cryoglobulinemia is Associated with Advanced Liver Fibrosis in Chronic Hepatitis C Patients
Gantsetseg Gantumur P-090 Association between Renal Function and Patients with Chronic Hepatitis C Infection
Ching-Chih Hu P-091 Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy
Yi-Chung Hsieh P-092 Real-world experience of elbasvir/grazoprevir in Taiwan: Experience of four medical centers in Chang Gung Medical System
YU-JU WEI P-093 Efficacy of Direct Acting Antivirals for Taiwanese Mixed Genotype Chronic Hepatitis C patients
Chi-Yi Chen P-094 Unexpected rate of early tumor occurrence in patients with HCV undergoing DAA therapy in 2017 : HCC, Cholangiocarcinoma, Lung Cancer, Gastric cancer, colon cancer
YU-JU WEI P-095 Daclatasvir plus asunaprevirtherapy for Taiwanese chronic hepatitis C patients with genotype 1b infection
Yen Cheng Chiu P-096 Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in southern Taiwan- a single center experience
Tyng Yuan Jang P-097 Lower viral load in thalassemic hepatitis C patients
Tyng Yuan Jang P-098 Lower viral load in thalassemia splenectomy patients
Huang-Wei Xu P-099 Is it possible to find anti-HCV-positive patients from hospital-based laboratory database?
Shih-Ming Huang P-100 The Efficacy and Safety of Viekira pak® in Chronic Hepatitis C Virus Infection: Real-World Experience of a Medical Center in Central Taiwan
Chia-Yen Dai P-101 MicroRNA expression profiles on hepatocellular carcinoma cells with different intracellular hepatitis C viral load
Chia-Yen Dai P-102 The Sofosbuvir plus daclatasvir therapy for Taiwanese patients with chronic hepatitis C virus infection
YU-JU WEI P-103 Recurrence of Hepatocellular Carcinoma after DAAs therapy in Taiwanese chronic HCV infection patients
Jung-chun Lin P-104 Real-world experience with interferon-free, direct acting antiviral therapies in HCV genotype 1b-infected patients with advanced liver disease in a medically underserved island
Wei Liang Chen P-105 "Elbasvir plus Grazoprevir for chronic genotype 1 hepatitis C virus infection: real-world experience at End of Treatment and Sustained Virological Response after treatment in a medical center"
Chou Tien-Shin P-106 Health-Related Quality of Life in Chronic Hepatitis C Carriers: A Community-based Study in Northeastern Region of Taiwan